A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure 1 YOSHITAKA IWANAGA * ,§ , YUSU GU * , THOMAS DIETERLE * , CRISTINA PRESOTTO † , PIERO DEL SOLDATO † , KIRK L PETERSON * , ENNIO ONGINI † , GIANLUIGI CONDORELLI * ,‡ and JOHN ROSS, JR * ,2 * Institute of Molecular Medicine, University of California, San Diego, California, USA; † Nicox Research Institute, Bresso, Milan, Italy; ‡ Laboratory of Molecular Cardiology, San Raffaele Biomedical Science Park, University "La Sapienza," Rome 00128, Italy; and § National Cardiovascular Center, Osaka, Japan 2 Correspondence: Department of Medicine, 9500 Gilman Dr. 0641, University of California, San Diego, La Jolla, CA 92093, USA. E-mail: jross@ucsd.edu <h3>SPECIFIC AIMS</h3> 1. Determine whether an NO-releasing derivative of enalapril, NCX-899 (N), improves cardiac function in a heart failure model of cardiomyopathic (CM) hamster 2. Compare the echocardiographic and hemodynamic effects of NCX-899 to those of the parent compound enalapril (E) and vehicle (V) in this model of heart failure <h3>PRINCIPAL FINDINGS</h3> <h3>1. NCX-899 significantly improved fractional shortening (FS) and decreased LV end-diastolic dimension (EDD) during 4 wk treatment compared with enalapril and vehicle.</h3>
/lp/fed-of-american-socs-for-experimental-biology/a-nitric-oxide-releasing-derivative-of-enalapril-ncx-899-prevents-48JZ5wXqWK